41st week of 2011 patent applcation highlights part 32 |
Patent application number | Title | Published |
20110250222 | ANTIGENIC POLYPEPTIDES OF CHLAMYDIA-RELATED BACTERIA FOR DIAGNOSIS AND VACCINE - The present invention relates to the disclosed transgenic peptides for use in the diagnosis of an infection by intracellular | 2011-10-13 |
20110250223 | HYBRID AND TANDEM EXPRESSION OF NEISSERIAL PROTEINS - Two or more Neisserial proteins are joined such that they are translated as a single polypeptide chain. Hybrid proteins are represented by the formula NH | 2011-10-13 |
20110250224 | ADJUVANT COMBINATIONS OF LIPOSOMES AND MYCOBACTERIAL LIPIDS FOR IMMUNIZATION COMPOSITIONS AND VACCINES - The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from | 2011-10-13 |
20110250225 | COMPOSITION COMPRISING A COMPLEXED (M)RNA AND A NAKED MRNA FOR PROVIDING OR ENHANCING AN IMMUNOSTIMULATORY RESPONSE IN A MAMMAL AND USES THEREOF - The present invention relates to an immunostimulatory composition comprising a) an adjuvant component, comprising or consisting of at least one (m)RNA, complexed with a cationic or polycationic compound, and b) at least one free mRNA, encoding at least one therapeutically active protein, antigen, allergen and/or antibody, wherein the immunostimulatory composition is capable to elicit or enhance an innate and optionally an adaptive immune response in a mammal. The inventive immunostimulatory composition may be a pharmaceutical composition or a vaccine. The invention furthermore relates to a method of preparation of the inventive immunostimulatory composition. The invention also relates to the use of the inventive immunostimulatory composition or its components (for the preparation of a pharmaceutical composition or a vaccine) for the treatment of various diseases. Finally, the invention relates to kits containing the inventive immunostimulatory composition, its components and/or the pharmaceutical composition or vaccine. | 2011-10-13 |
20110250226 | COMPOSITION CONTAINING EXTRACTS OF FUSCOPORIA OBLIQUA, GANODERMA LUCIDUM AND PHELLINUS LINTEUS FOR PROMOTING THE PROLIFERATION OF HEMATOPOIETIC STEM CELLS - A composition for promoting the proliferation of hematopoietic stem cells, which contains mushroom extracts, and more particularly to a composition and functional food for promoting the proliferation of hematopoietic stem cells, which contain, as active ingredients, an | 2011-10-13 |
20110250227 | COMPOSITION FOR TREATMENT OF THE SKIN - A natural composition comprising myrtle berries; seaweed; and at least two of tea tree oil, lemongrass oil, evening primrose oil, ginger, jojoba oil, neem oil, and chamomile, and uses thereof for treatment of skin conditions. | 2011-10-13 |
20110250228 | Compositions and Methods for Identifying and Targeting Cancer Cells of Alimentary Canal Origin - Screening and diagnostic reagents, kits and methods for metastatic colorectal cancer or primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines compositions and methods of for treating and preventing metastatic colorectal cancer or primary and/or metastatic stomach or esophageal cancer are disclosed. | 2011-10-13 |
20110250229 | ALLOGENEIC CANCER CELL-BASED IMMUNOTHERAPY - Cell-based immunotherapy (e.g., immunization or vaccination) may be improved by frequent administration to a human subject of allogeneic cancer cells secreting a modified heat shock protein (e.g., gp96), depletion of B cells in the subject, or both. Antigen (e.g., epitope derived from neoantigen or tumor antigen of allogeneic or syngeneic cancer cells) may induce a specific immune response in the subject. For example, the epitope bound in an immunogenic complex with the secreted heat shock protein may be obtained from allogeneic cancer cells coexpressing both secreted gp96 and antigen, or from syngeneic cancer cells of the subject expressing only antigen. | 2011-10-13 |
20110250230 | CELL CAPABLE OF EXPRESSING EXOGENOUS GITR LIGAND - Disclosed are: a cell capable of expressing an exogenous GITRL or an exogenous GITRL derivative; a method for producing the cell; a therapeutic or prophylactic agent comprising the cell as an active ingredient; use of the cell in the manufacture of a therapeutic or prophylactic agent; a method comprising a step of administering the cell to a subject; a viral vector carrying a gene encoding a GITRL or a GITRL derivative; a therapeutic or prophylactic agent comprising the viral vector as an active ingredient; use of the viral vector in the manufacture of a therapeutic or prophylactic agent; and a method comprising a step of administering the viral vector to a subject. | 2011-10-13 |
20110250231 | METHOD OF USING PUNICIC ACID TO ENHANCE IMMUNE RESPONSE AND PREVENT METABOLIC DISORDERS - Disclosed is a method of enhancing the immune response of an animal, including mammals and humans, to prevent or ameliorate immunoinflammatory diseases such as Inflammatory Bowel Disease, increase immune system development, maintain or increase CD4 | 2011-10-13 |
20110250232 | DNA-Transfection System for the Generation of Infectious Influenza Virus - The present invention is based on the development of a dual promoter system (preferably a RNA pol I-pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome. The viral product of the system is produced when the plasmids of the system are introduced into a suitable host cell. One application of the system is production of attenuated, reassortant influenza viruses for use as antigens in vaccines. The reassortant viruses generated by cotransfection of plasmids may comprise genes encoding the surface glycoproteins hemagglutinin and neuraminidase from an influenza virus currently infecting the population and the internal genes from an attenuated influenza virus. An advantageous property of the present invention is its versatility; the system may be quickly and easily adapted to synthesize an attenuated version of any RNA virus. Attenuated or inactivated RNA viruses produced by the present invention may be administered to a patient in need of vaccination by any of several routes including intranasally or intramuscularly. | 2011-10-13 |
20110250233 | ANTITUMOR VACCINATION USING ALLOGENEIC TUMOR CELLS EXPRESSING ALPHA (1,3)-GALACTOSYLTRANSFERASE - The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an α (1,3) galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The α galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal. | 2011-10-13 |
20110250234 | Immunogenic Polypeptides Encoded by MAGE Minigenes and Uses Thereof - The invention discloses immunogenic polypeptides comprising several MAGE-specific antigen epitopes selected from different (i.e. discrete) members of the MAGE protein family, nucleic acids coding therefor, recombinant viruses and/or cells comprising said nucleic acids, and compositions thereof. Methods for eliciting or inducing MAGE-specific immune responses utilizing the aforementioned immunogenic agents are also disclosed. | 2011-10-13 |
20110250235 | PRODUCTION OF A SACCHARIDE COMPOSITION COMPRISING GLUCANS AND MANNANS BY ALKALINE AND ACID HYDROLYSIS OF YEAST CELLS - The present invention is directed to a method of production of an immunostimulatory composition having a saccharide fraction, the method including the steps of hydrolyses of yeast cells and recovering the soluble fraction. The saccharide fraction having composition thus obtained may be incorporated as a food or beverage component or be used as a pharmaceutical for treatment of specific conditions. | 2011-10-13 |
20110250236 | STEM CELLS DERIVED FROM THE CAROTID BODY AND USES THEREOF - Adult stem cells obtained from the carotid body, characterized in that they are positive for the phenotypic marker GFAP (glial fibrillary acidic protein) and negative for the phenotypic markers TH (tyrosine hydroxylase) and nestin, are described. These stem cells can undergo proliferation, self-renewal and differentiation to progenitor cells and differentiated cells. Said stem cells, progenitor cells and differentiated cells, expanded by any method, can be used in the treatment of neurodegenerative diseases such as Alzheimer's disease or Parkinson's disease. | 2011-10-13 |
20110250237 | IMMUNOGENIC AMPHIPATHIC PEPTIDE COMPOSITIONS - The present application pertains to a composition, comprising (a) amphipathic peptides; (b) lipids and (c) at least one immunogenic species. Respective compositions are suitable for immunogenic species transport and delivery, for example for systemic or local delivery to a mammal. Also provided are pharmaceutical compositions, comprising respective compositions. Methods of forming the foregoing are also provided. | 2011-10-13 |
20110250238 | SYSTEM FOR THE COLON DELIVERY OF DRUGS SUBJECT TO ENZYME DEGRADATION AND/OR POORLY ABSORBED IN THE GASTROINTESTINAL TRACT - Said invention refers to a pharmaceutical form for selective colon delivery of drugs or bioactive molecules degraded and/or poorly absorbed in the gastrointestinal tract. The system comprises a core consisting of the active ingredient, and a protease inhibitor layer and/or an absorption enhancer layer, said core being separated from these layers by means of a polymer that swells and/or dissolves and/or is degraded when in contact with the biological fluids present in the gastro-intestinal tract; depending on the thickness of the polymeric layer, the release of the drug can be modulated with respect to the inhibitor and/or promoter. | 2011-10-13 |
20110250239 | PHARMACEUTICAL AND/OR COSMETIC COMPOSITION FOR TREATING THE SKIN - The present invention concerns the pharmaceutical and cosmetic application of biocolloids, which originate from the mixture of a nanoemulsion and at least one water-soluble plant extract such as an extract from | 2011-10-13 |
20110250240 | IMMUNE ENHANCING COMPOSITIONS AND METHODS OF USE THEREOF - A method of administering parenterally, particularly intramuscularly, glutamine and cystine and glycine plus selenium; or lactalbumin plus selenium; or lactalbumin and glutamine and cystine and glycine plus selenium, through a long-acting pharmaceutically acceptable carrier to a patient. The method comprises injecting a mixture of glutamine, cystine, glycine, lactalbumin and selenium in order to maintain the mixture systemically or locally for a sufficient time period so as to maintain blood levels of glutathione within an improved therapeutic range. | 2011-10-13 |
20110250241 | INJECTION-MOULDED WATER-SOLUBLE CONTAINER - A rigid, water-soluble container is made of an injection molded poly(vinyl alcohol) and/or a cellulose ether, which container encases a fabric care, surface care or dishwashing composition; and a capsule container comprising at least two components made of one or more material(s) that can be molded and which are water soluble or water dispersible or in which a substantial part of the surface of these components is water soluble or water dispersible so as to leave perforations throughout the wall when the capsular container is placed in contact with an aqueous environment. The container has one to six compartments, preferably one, two or three, the content of the various compartments being accessible to the aqueous environment when the capsular container is exposed to such an aqueous environment. The accessibility time of the various compartments is the same or different from one compartment to another compartment, with the proviso that the content of the container is not a fabric care, surface care or dishwashing composition. | 2011-10-13 |
20110250243 | NANOPARTICLE COMPOSITIONS - Poly(ethylene carbonate) (PEC) nanoparticles comprising pharmacologically active substances, their production method and their use for sustained release of the pharmacologically active agent after application are described. | 2011-10-13 |
20110250244 | MELT-COATED PHARMACEUTICAL COMPOSITION WITH FAST RELEASE - The present invention relates to a process for producing a solid, coated pharmaceutical composition by a melt coating process. The process is adapted to provide a solid, coated pharmaceutical composition by melt coating, which has a fast release. | 2011-10-13 |
20110250245 | USE OF STINGING CELLS/CAPSULES FOR THE DELIVERY OF ACTIVE AGENTS TO KERATINOUS SUBSTANCES - A composition of matter comprising an agent beneficial to a non-skin keratinous substance and at least one stinging capsule and methods of use are disclosed. | 2011-10-13 |
20110250246 | Oil-In-Water External Skin Preparation - The present invention provides an oil-in-water external skin preparation having thread-forming property and an excellent time-dependent stability of the thread-forming property, penetrating well into skin, providing richness and no stickiness when the applied preparation gets dry. The oil-in-water external skin preparation includes (a) 0.01 to 3.0% by mass of polyacrylic acid or metal salt thereof, (b) 0.01 to 1.0% by mass of alkyl-modified carboxyvinyl polymer, (c) 1.0 to 10.0% by mass of polyethylene glycol having an average molecular weight of 1000 or more to 50000 or less of, and (d) 0.5 to 20.0% by mass of oil. | 2011-10-13 |
20110250247 | TABLETTING OF ERYTHRITOL - Erythritol having a specific surface area greater than 0.25 m | 2011-10-13 |
20110250248 | External preparation for skin - An external preparation for the skin containing isononyl 2-ethylhexanoate and/or 2-ethylhexyl 2-ethylhexanoate (i.e., component (a)); an oil-in-water emulsion type skin cosmetic composition containing the ingredient (a), (b) one or more ingredients selected from higher fatty acids and higher alcohols which are solid to semi-solid at an ordinary temperature (25° C.), (c) a homopolymer, copolymer, cross polymer, or mixture containing one or more ingredients selected from 2-acrylamide-2-methylpropane sulfonic acid and acrylic acid and its derivatives as constituent units and (d) one or more ingredients selected from nonionic surfactants having an HLB value of 9 or more; and an oil-in-water or a water-in-oil emulsion type sunscreen cosmetic composition containing (a) 2-ethylhexyl 2-ethylhexanoate and/or isononyl 2-ethylhexanoate, (b) an ultraviolet absorber, (c) an ultraviolet scatterer and (d) a silicone oil. | 2011-10-13 |
20110250249 | Low Energy, Cold Process Formulation Aid - Provided are cold process formulation aids, methods for their manufacture, and personal care products made using them. The cold processing aids include a wax and a polymer having a backbone and a plurality of pendant groups thereon that are pendant ionic or ionizable groups, or pendant groups having at least one permanent dipole that includes an alcohol, thiol, ester, amide, imide, imine, or nitrile moiety. The backbone can be an aliphatic backbone, a polysaccharide backbone, a siloxane backbone, or a polyamide backbone. Also provided is a method of making personal care products using the cold processing aid. | 2011-10-13 |
20110250250 | COMPOSITIONS AND METHODS FOR SPF ENHANCEMENT BY HIGH CONCENTRATION COSMETIC POWDER FORMULATIONS - The present disclosure relates generally to cosmetic formulations wherein cosmetic powder materials potentiate the UV protection factor provided by an organic sunscreen. The present disclosure relates particularly, but not by way of limitation, to UV-protecting cosmetic formulations comprising cosmetic powders and having low loadings of organic sunscreens. | 2011-10-13 |
20110250251 | Cosmetic Methods And Compositions For Repairing Human Skin - The present invention relates to methods and compositions for repairing adverse effects of the environment, daily stress, sun exposure, or pre-mature aging on human skin, comprising applying to the skin, prior to a period of bodily rest, a topical composition that contains resveratrol or a derivative thereof and at least one DNA repair enzyme. | 2011-10-13 |
20110250252 | COLOURING TECHNIQUES - A method for masking the appearance of silicon in a range of compositions is described. | 2011-10-13 |
20110250253 | Antimicrobial treatment of synthetic nonwoven textiles - Highly active, leach-resistant, antimicrobial nonwoven textiles are prepared by treating at least one surface of the nonwoven material with an anionic polyelectrolyte, such as carboxymethyl cellulose, alginic acid, poly(acrylic acid) etc and at least one select quaternary ammonium antimicrobial agent. The textiles of the invention, and products produced from them, exhibit a highly effective quick kill rate, for example a log 4 CFU reduction within a 5 minute contact time, against microbes such as fungi and gram (−) and gram (+) bacteria. | 2011-10-13 |
20110250254 | ANTIMICROBIAL COMPOSITIONS AND USES - An agent comprising the compound according to general formula (I) wherein R | 2011-10-13 |
20110250255 | DRUG COATED STENT WITH ENDOSOME-DISRUPTING CONJUGATE - A stent is provided with a drug-eluting layer disposed on at least a portion of its surface, wherein the drug-eluting layer comprises an endosome-disrupting agent and a pharmaceutical agent. In an embodiment, the endosome-disrupting agent, when taken up through endocytosis into living cells, causes lysis of endosomes containing the endosome-disrupting agent. The pharmaceutical agent can accompany the endosome-disrupting agent into the living cells. | 2011-10-13 |
20110250256 | Dissolvable Nano Web Porous Film and Method of Preparing the Same - A dissolvable nano web porous film has a network structure and a large specific surface area. The network structure is formed by stacking nano fibers that have a thickness of 10˜50,000 nm. The nano fibers are formed of a composition comprising nano fiber forming polymer, a gelling agent, a plasticizer, an optional active component and an optional additive. A method of preparing a dissolvable nano web film comprises producing a polymer melt or solution formed of a composition that comprises a nano fiber forming polymer, a gelling agent, a plasticizer, an optional active component and additives, spinning the melt or solution to form a nano web porous film having nano webs stacked in a network structure, drying the nano web porous film, and stabilizing the nano web porous film. The porous film has a 5˜5000 times higher specific surface area and a 2˜20 times faster dissolving time than a conventional film. The dissolvable nano web porous film has excellent dissolvability and solubility. | 2011-10-13 |
20110250257 | FIBROUS TISSUE SEALANT AND METHOD OF USING SAME - Disclosed herein is a fibrous tissue sealant in the form of an anhydrous fibrous sheet comprising a first component which is a fibrous polymer containing electrophilic or nucleophilic groups and a second component capable of crosslinking the first component when the sheet is exposed to an aqueous medium, thereby forming a crosslinked hydrogel that is adhesive to biological tissue. The fibrous tissue sealant may be useful as a general tissue adhesive for medical and veterinary applications such as wound closure, supplementing or replacing sutures or staples in internal surgical procedures, tissue repair, and to prevent post-surgical adhesions. The fibrous tissue sealant may be particularly suitable for use as a hemostatic sealant to stanch bleeding from surgical or traumatic wounds. | 2011-10-13 |
20110250258 | TUMOR-SPECIFIC DELIVERY OF THERAPEUTIC AGENTS VIA LIPOSOMASE - is an obligate anaerobe that can infect hypoxic regions within experimental tumors. We found that mice bearing large, established tumors were often cured when treated with | 2011-10-13 |
20110250259 | Method of treating and preventing breast diseases and breast cancer with medicated formula - Breast cancer is a common cancer in women. Early diagnosis and treatments are vital for better outcomes. This formula consists of a liquid anti-disease anti-cancer formula that can be delivered to the source where breast cancer begins. | 2011-10-13 |
20110250260 | INHIBITION OF BRAIN ENZYMES INOLVED IN CEREBRAL AMYLOID ANGIOPATHY AND MACULAR DEGENERATION - A method of treating or inhibiting progress of dementia and/or macular degeneration in a mammal involves administering compositions containing siRNA to heme oxygenase-1 (HO-1) or heme oxygenase-2 (HO-2), a matrix metalloproteinase (MMP) inhibitor, a caspase inhibitor, or a metalloporphyrinan in a manner that permits access to brain sites and/or the macula of the patient. | 2011-10-13 |
20110250261 | CIRCULAR DUMBBELL DECOY OLIGODEOXYNUCLEOTIDES (CDODN) CONTAINING DNA BINDINGS SITES OF TRANSCRIPTION - The present invention provides a circular dumbbell oligodeoxynucleotide (CDODN) comprising two loop structures and a stem structure, wherein the stem structure comprises a nucleotide sequence capable of binding the DNA-binding domain of a transcriptional factor. The present invention further provides a pharmaceutical composition comprising said CDODN. The pharmaceutical composition can be used for treating and/or preventing a disease or disorder related to such a transcriptional factor. The present invention also provides a method for treating and/or preventing a disease or disorder related to such a transcriptional factor, comprising administering to the subject a therapeutically effective amount of a CDODN comprising two loop structures and a stem structure, wherein the stem structure comprises a nucleotide sequence capable of binding the DNA-binding domain of the transcriptional factor. | 2011-10-13 |
20110250262 | METHOD FOR PRODUCING LIPOSOME AND METHOD FOR DISSOLVING CHOLESTEROL - Disclosed is a method for producing a liposome, which comprises: a first mixing step wherein one or more lipids are mixed with an aqueous solution containing a water-miscible organic solvent; a heating step wherein the mixture obtained by mixing the lipids with the aqueous solution is heated to a temperature at which the lipids are dissolved in the aqueous solution; and a cooling step following the heating step, wherein the resulting mixture is cooled down to a temperature at which a liposome is produced. Uniform-sized liposomes having a high encapsulation rate can be easily obtained by the method. | 2011-10-13 |
20110250263 | PROTEIN AND NUCLEIC ACID DELIVERY VEHICLES, COMPONENTS AND MECHANISMS THEREOF - Complex viruses are assembled from simple protein subunits by sequential and irreversible assembly. During genome packaging in bacteriophages, a powerful molecular motor assembles at the special portal vertex of an empty prohead to initiate packaging. An aspect of the invention relates to the phage T4 packaging machine being highly promiscuous, translocating DNA into finished phage heads as well as into proheads. Single motors can force exogenous DNA into phage heads at the same rate as into proheads and phage heads undergo repeated initiations, packaging multiple DNA molecules into the same head. This shows that the phage DNA packaging machine has unusual conformational plasticity, powering DNA into an apparently passive capsid receptacle, including the highly stable virus shell, until it is full. These features allow for the design of a novel class of nanocapsid delivery vehicles. | 2011-10-13 |
20110250264 | METHOD FOR FORMULATING LARGE DIAMETER SYNTHETIC MEMBRANE VESICLES - The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated. | 2011-10-13 |
20110250265 | Vaccine Preparation for Neospora Caninum Infection - A vaccine preparation characterized in that | 2011-10-13 |
20110250266 | LIPOSOMAL SYSTEMS COMPRISING SPHINGOMYELIN - The present disclosure provides a liposomal system comprising an aqueous medium having dispersed therein liposomes encapsulating in their intraliposomal aqueous compartment at least one active agent, the aqueous medium being in iso-osmotic equilibrium with said intraliposomal aqueous compartment, the liposomes having a membrane comprising a liposome forming lipids, at least one of which being sphingomyelin (SPM), the liposomal system having increased stability as compared to the same liposomes free of SPM, and in one embodiment being stable during long-term storage, said stability being characterized in that no more than 30% of the at least one active agent is present in the aqueous medium after said storage. Further provided by the present disclosure are a method for storage of liposomes making use of the liposomal system; use of the liposomal system for the treatment of a medical condition or for the diagnostic of a medical condition; a pharmaceutical or diagnostic composition comprising the liposomal system, and a method of treating or diagnosing of a medical condition comprising administering to a subject an amount of the liposomal system. | 2011-10-13 |
20110250267 | USE OF DIINDOLYLMETHANE-RELATED INDOLES FOR THE TREATMENT AND PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS ASSOCIATED CONDITIONS - The present invention includes compositions and methods for the treatment and prevention of conditions associated with Respiratory Syncytial Virus (RSV) infection. RSV-associated conditions include acute infections in mammals, typically bronchiolitis and pneumonia, and post-infectious chronic respiratory conditions. In particular, the present invention describes new therapeutic and preventative uses for 3,3′-diindolylmethane (DIM), or a DIM-related indole, alone or in combination with an inhibitor of a membrane bound Epidermal Growth Factor Receptor (EGFR) inhibitors, to treat conditions associated with exposure to RSV. | 2011-10-13 |
20110250268 | Compositions and Methods for Inhibiting Gastric Acid Secretion - The present invention is related to novel oral compositions comprising an irreversible gastric H | 2011-10-13 |
20110250269 | HIGHLY EFFICIENT AND LONG-ACTING SLOW-RELEASE FORMULATION OF POORLY SOLUBLE DRUGS AND PREPARATION METHOD THEREOF - A high-efficacy, long-acting, slow-release formulation of the poorly soluble drug, comprising solid dispersion of the poorly soluble drug, silica nanoparticles loaded with the poorly soluble drug, matrix material, and release enhancer, wherein the mass ratio of these components is solid dispersion of the poorly soluble drug: silica nanoparticles loaded with the poorly soluble drug: matrix material: release enhancer=1: 0.5˜1.25: 0.1˜0.3: 0.1˜0.3; the said solid dispersion of the poorly soluble drug contains povidone K30, soybean lecithin, and acrylic resin IV, wherein the mass ratio of the drug and the accessory materials is poorly soluble drug: povidone K30: soybean lecithin: acrylic resin IV=1: 1-3: 0.3˜0.8: 0.2˜0.5. Compared with the existing formulations, the in vivo half life of the high-efficacy, long-acting formulation of the poorly soluble drug disclosed in this invention is 2.3˜14.8 times longer while the mean residence time (MRT) of which is 7.94˜4.52 times longer; when tested in vivo in Beagle dogs, this new formulation of the poorly soluble drug presents a smoother concentration-time curve and reaches a continuous release for 72 hours. This invention discloses its preparation method. | 2011-10-13 |
20110250270 | Compositions containing a capillary-active system with application-relevant diffferentiability and their use - A composition that has a capillary-active system C optionally containing a capillary activator system CA consisting of drugs that increase blood flow, stabilize the vascular wall, and/or dilate the blood vessels; and/or a capillary-protective system CP comprising drugs for endothelial stabilization, lipoprotein protection, and for stabilization of leukocytes/platelets; and/or a capillary energy supply system CE comprising redox systems and cofactors in energy provision and energy carriers. This system C is combined with a selective action system S. The compositions are useful, systemically or enterally, especially for the selective control, for example, of structural changes, functional disturbances of the target organs in question (hair, skin, cerebrum, skeleton, muscles, gastrointestinal tract, eyes) as supplements (food supplements, supplementary balanced diet, dietary components), or pharmaceutical agents. | 2011-10-13 |
20110250271 | SPACED DRUG DELIVERY SYSTEM - The present invention provides to a method of administration of two or more therapeutically active agents comprising orally administering to a patient a spaced drug delivery system, wherein the time of release of the two or more therapeutically active agents is designed to provide desired control on the disease condition. The present invention also provides a method of administration of two or more therapeutically active agents comprising orally administering to a patient a spaced drug delivery system at a specified time prior to food intake by the patient. The present invention further provides a spaced drug delivery system that releases two or more antidiabetic agents at different times after oral administration, for the treatment of diabetes mellitus or conditions associated with diabetes mellitus. More particularly, the present invention provides a spaced drug delivery system that immediately releases one or more antidiabetic agents after oral administration of the system, and releases as a pulse one or more antidiabetic agents in a reliable manner at about a predetermined time after oral administration of the system. | 2011-10-13 |
20110250272 | SOLID, ORODISPERSIBLE AND/OR DISPERSIBLE COMPOSITION, WITHOUT AN EXCIPIENT OF KNOWN EFFECT AND ITS PROCESS OF PREPARATION - The present invention relates to a solid, orodispersible and/or dispersible composition comprising (a) from 0.1 to 59% by weight of at least one active substance with particle size no exceeding 50 μm; (b) from 40 to 99% by weight of at least one diluent without known effect, non water-soluble; (c) from 0.1 to 15% by weight of at least one disintegrating agent; and (d) from 0.05 to 10% by weight at least of one sweetening agent with particle size not exceeding 50 μm, percentages by weight being expressed compared to the total weight of the aforementioned composition. The present invention also relates to the use of said composition as a drug, a food supplement or in cosmetics and a method of preparation of an orodispersible and/or dispersible compound implementing said composition. | 2011-10-13 |
20110250273 | COMPOSITIONS OF PROTON PUMP INHIBITORS, KITS AND METHODS OF THEIR USE TO TREAT DIABETES - The present invention relates to compositions, kits and methods of treating diabetes. More specifically, compositions of at least one proton pump inhibitor, kits and methods of their use to treat diabetes. | 2011-10-13 |
20110250274 | ESTRIOL FORMULATIONS - Disclosed herein are oral dosage forms and methods of their use, in particular oral dosage systems for the delivery of estriol compounds. Embodiments described herein relate to rapidly disintegrating oral dosage formulations that disintegrate in the saliva of the buccal and/or sublingual and/or esophageal cavity. Oral dosage forms described herein relate to stabilized amorphous and nanocrystalline forms of the active ingredients of the formulations. | 2011-10-13 |
20110250275 | PHARMACEUTICAL COMPOSITIONS AND METHODS RELATING TO INHIBITING FIBROUS ADHESIONS OR INFLAMMATORY DISEASE USING LOW SULPHATE FUCANS - Compositions and methods involving administration of agents useful for the treatment, prevention, inhibition, etc., of inflammatory disease or fibrous adhesions using low sulphate fucans and, if desired, one or more other anti-inflammatory disease or anti-fibrous adhesion agent. | 2011-10-13 |
20110250276 | Cosmetic Composition Containing Acetylated Oligoglucuronans - The present invention relates to the field of cosmetic and dermopharmaceutical compositions. It concerns oligomer compounds of D-glucuronic acid or D-glucuronate with a β (1-4) sequence (or oligoglucuronans) containing a degree of acetylation specifically between 8.7±0.5 and 9.2±0.5% by weight of O—CO—CH | 2011-10-13 |
20110250277 | Modified release compositions comprising tacrolimus - A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents. | 2011-10-13 |
20110250279 | CONTROLLED-RELEASE COMPOSITION FOR PRODUCING SUSTAINED-RELEASE PREPARATION CONTAINING UDENAFIL - This invention relates to a controlled-release composition for producing a sustained-release preparation containing udenafil, including (A) udenafil and a pharmaceutically acceptable salt, (B) a solubility modulator, (C) an adsorbent, and (D) a hydrophilic polymer. This controlled-release composition for producing a sustained-release preparation containing udenafil releases drugs constantly regardless of the pH level in the gastrointestinal tract, and thus freely controls the drug release time within the range of 3˜24 hours, and reduces the variability in the effect of drugs among individuals. Also, this composition can be produced into a sustained-release preparation which has an optimum condition for expressing the effect of drugs in the treatment of diseases including pulmonary arterial hypertension, hepatic portal vein hypertension, benign prostatic hyperplasia, and the like, which can be treated by udenafil and which requires the long-term drug administration. Also, this composition can control the release of drugs in accordance with the time taken for the absorption thereof when the drugs are applied to a living body, and thus can be valuably used in preventing and treating erectile dysfunction. | 2011-10-13 |
20110250280 | MICROENCAPSULATION PROCESS OF SERTOLI CELLS, MICROCAPSULES OBTAINED AND THEIR USE FOR PREVENTION AND CURE OF TYPE I DIABETES MELLITUS - The invention relates to the use of Sertoli cells (SC) microencapsulated into hydrogel-based microcapsules, for the prevention and/or treatment of Type 1 diabetes mellitus (T1DM) and to a process for producing microcapsules, preferably shaped as microspheres. | 2011-10-13 |
20110250281 | Fexofenadine Microcapsules and Compositions Containing Them - The present invention provides a pharmaceutical composition comprising taste-masked immediate release microcapsules which comprise fexofenadine and a water-insoluble polymer coating. These microcapsules and the pharmaceutical compositions comprising them have suitable drug content and desirable pharmaceutical properties, including a quick dissolution rate of fexofenadine combined with a taste masking effect. | 2011-10-13 |
20110250282 | Prolonged Release Formulations Comprising an 2-Oxo-1-Pyrrolidine Derivative - The present invention relates to a pharmaceutical composition comprising Levetiracetam, Brivaracetam or Seletracetam as active ingredient, the invention relates specifically to a prolonged release formulation. | 2011-10-13 |
20110250283 | Pentablock Polymers - Novel pentablock polymers comprising PGA-PCL-PEG-PCL-PGA or PEG-PCL-PLA-PCL-PEG, wherein PEG is polyethylene glycol, PCL is poly(ε-caprolactone), PGA is poly(glycolic acid), and PLA is poly(lactic acid). | 2011-10-13 |
20110250284 | Nanoparticles for Use as Synthetic Platelets and Therapeutic Agent Delivery Vehicles - The invention relates to synthetic platelet compositions and methods useful in diminishing bleeding and blood loss. The synthetic platelets of the invention can comprise a biocompatible, biodegradable polymer, including, for example, a poly(lactic-co-glycolic acid)-poly-L-lysine (PLGA-PLL) block copolymer, having conjugated PEG arms terminating with RGD motif containing peptides. The invention further comprises compositions and methods useful in the delivery of therapeutic agents. | 2011-10-13 |
20110250285 | OIL-IN-OIL EMULSIFIED POLYMERIC IMPLANTS CONTAINING A HYPOTENSIVE LIPID AND RELATED METHODS - Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the polymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma. | 2011-10-13 |
20110250286 | Micro Particles for Oral Delivery in Animals - A system for the controlled release of one or more physiologically or pharmacologically active substances, comprising compositions in the form of micro particles or granules, particularly for use in the zootechnical and/or veterinary field. The micro particles include a core which contains one or more substances having a pharmacological action, food supplements or diagnostic media, said one or more substances being characterized by the presence, within their chemical structure, of a basic functional group, specifically including an amine functional group. The core comprises also one or more carboxylic acids and/or their salts and eventually one or more excipients. Said core is coated by an outer layer of fats or waxes, and preferably by a mixture of glyceride of fatty acids. | 2011-10-13 |
20110250287 | One step removal of selected molecules from body fluid and tissue - A method for reducing the number of selected antibodies in a subject's blood, the method comprising removing blood from the subject, passing the blood along an enclosed pathway, wherein the pathway comprises one or more semi-permeable hollow fibers with one or more membranes having surfaces positioned substantially perpendicular to the length of the one or more hollow fiber and antigens specific for the antibodies immobilized on the one or more membranes, returning the treated blood to the internal circulation of the subject, wherein the returned treated blood has a reduced number of selected antibodies compared to before treatment. | 2011-10-13 |
20110250288 | FUNGICIDAL COMPOSITIONS AND METHODS OF ENHANCING TURFGRASS - The present disclosure provides fungicidal compositions and methods of enhancing vegetation, e.g. turfgrass. The composition may be a combination of chlorothalonil and malachite green dye. Malachite green oxalate is preferred. This composition is mixed with water and inert ingredients such as surfactants and other inert ingredients. A phonosphonate compound may be added, such as a phosphite. Potassium phosphite may be used. Urea phosphite is preferred. The composition is mixed in water with inert ingredients such as surfactants and other inert ingredients. | 2011-10-13 |
20110250289 | BONE SUBSTITUTE AND METHOD FOR THE PREPARATION THEREOF - The invention relates to a material that can be used as a bone substitute and to a method for the preparation thereof. The material comprises an organic phase (I) comprising striated collagen fibrils constituted of collagen I triple helices, said fibrils being organized over a large distance according to a 3D geometry associating aligned domains and cholesteric domains, and also isotropic domains where they are not organized; and a mineral phase (II) comprising apatite crystals having a hexagonal crystalline structure, space group 6/m, comprising at least calcium ions and phosphate ions; the axis c of said apatite crystals of the mineral phase is coaligned with the longitudinal axis of the striated collagen fibrils of the organic phase and the collagen content in the material is at least 75 mg/cm | 2011-10-13 |
20110250290 | DISINFECTANT COMPOSITIONS - The invention is a method and composition for treating biofilm using a silver deposition compound. In preferred embodiments of the invention, the anti-biofilm agent is used to preserve or disinfect plant material, including seeds, leaves, stems, vessels, flowers, roots and fruits. | 2011-10-13 |
20110250291 | USE OF ARSENIC FOR CANCER THERAPY PROTECTION - A method of inhibiting damage to non-cancerous cells in a human subject during chemotherapeutic treatment or radiation treatment of cancer cells in the human subject includes administering to the human subject arsenic and/or one or more compounds of arsenic in a therapeutically effective amount prior to treatment with radiation or one or more chemotherapeutic agents. | 2011-10-13 |
20110250292 | COMPOSITION FOR IMPROVING RADIOTHERAPY FOR CANCER - Disclosed is a composition for improving radiotherapy for cancer, containing tetra-arsenic oxide (As | 2011-10-13 |
20110250293 | Present invention relates to compositions and methods for the treatment of topical skin conditions, comprising of shea butter, jojoba oil, dihydrogen oxide, Stearic acid, Anhydrous Magnesium Sulphate, Zinc Oxide, Glycerin and a suitable amount of a Pharmaceutically acceptable carrier, one or both of the following: Cocoa butter and or petroleum jelly. - The present invention relates to compositions and methods for the treatment of topical skin conditions, comprising of shea butter, jojoba oil, dihydrogen oxide, Stearic acid, Anhydrous Magnesium Sulphate, Zinc Oxide, Glycerin and a suitable amount of a pharmaceutically acceptable carrier, one or both of the following: Cocoa butter and or petroleum jelly. | 2011-10-13 |
20110250294 | COMBINATIONS OF PRESERVATIVE COMPOSITIONS FOR OPHTHALMIC FORMULATIONS - The present invention provides a preservative composition for protecting ophthalmic solutions from microbial attack comprising a combination of benzalkonium ion and An oxy-chlorite moiety, e.g. purite wherein the combined concentrations of benzalkonium ion and An oxy-chlorite moiety, e.g. purite in said composition is sufficient to provide protection against microbial attack when said composition is added to an ophthalmic solution as compared to said ophthalmic solution having the same concentration of benzalkonium ion and An oxy-chlorite moiety, e.g. purite, alone. | 2011-10-13 |
20110250295 | AQUEOUS COMPOSITION FOR INACTIVATING SPORULATED AND/OR NON-SPORULATED COCCIDIAN PARASITES - The invention relates to an aqueous composition for inactivating sporulated and/or non-sporulated Coccidia parasites comprising 15 to 115 ppm chlorine dioxide and 0.01 to 1 wt-% of an anionic surfactant having one or more C | 2011-10-13 |
20110250296 | REVERSE VITAMIN K EFFECT VIA PHOTODYNAMIC OXIDATION TARGETED AT VASCULAR ENDOTHELIUM, FIBRIN AND BLOOD PLATELETS - A formulation or preparation for treating and preventing arterial and venous thrombi is provided. This preparation includes a non-metal containing photodynamic dye and a fat soluble vitamin. A method of administration for treatment and prophylaxis of arterial and venous thrombi is also provided. This method includes steps of: combining a non-metal containing photodynamic dye and a fat soluble vitamin; combining the non-metal containing photodynamic dye and fat soluble vitamin with a sodium solution; and administering the combination of non-metal containing photodynamic dye, fat soluble vitamin, and sodium solution as an intravenous drip. | 2011-10-13 |
20110250297 | Treatment of Hyperproliferative Disorders Using Cardiac Glycosides - Provided are methods and compositions for treating and preventing hyperproliferative disorders such as psoriasis by administration of a cardiac glycoside alone or in combination locally or systemically with a calciotropic agents and/or a diffusion-limiting component, such a vasoconstrictor or collagen barrier. | 2011-10-13 |
20110250298 | Composition to help protect a user against liver damage from alcohol consumption - The present invention is a composition that can be taken by a user with an alcohol consuming lifestyle, to protect the user from liver damage as a result of consuming alcohol. The composition contains milk thistle extract, dandelion root, artichoke extract, vitamin E, selenium, thiamin, riboflavin, niacin, pyridoxine and cyanocobalamin. The alcohol is ethyl alcohol based drinks such as liquor, beer, wine or a combination of ethyl alcohol based drinks, liquor, beer or wine. The composition can be taken by a user in the form of a pill, a tablet or a capsule. | 2011-10-13 |
20110250299 | ORGANOGEL COMPOSITIONS AND PROCESSES FOR PRODUCING - The present invention is directed towards organogel compositions comprising a phospholipid composition. Processes for producing such organogel compositions are further disclosed. The present invention is also directed towards uses of the novel organogel compositions in foods or beverages, cosmetics, personal care products, as a drug delivery vehicle or as a carrier of any desired compound. | 2011-10-13 |
20110250300 | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATING TO OXIDATIVE STRESS - The present invention features methods for treating or preventing conditions, diseases, or disorders related to oxidative stress. In one embodiment, the method increases Nrf2 biological activity or expression. In particular, the invention provides for the treatment or prevention of diseases relating to oxidative stress including emphysema, sepsis, septic shock, ischemic injury, cerebral ischemia and neurodegenerative disorders, meningitis, encephalitis, hemorrhage, cerebral ischemia, heart ischemia, cognitive deficits and neurodegenerative disorders. | 2011-10-13 |
20110250301 | WATER INSOLUBLE HELYCHRISUM EXTRACT, PROCESS FOR PREPARING THE SAME AND USES THEREOF - The present invention relates to a water insoluble helychrisum extract, a process for preparing the same and its use for preparing pharmaceutical compositions for oral and/or topical administration. Furthermore, the present invention relates to the pharmaceutical compositions including said extract. | 2011-10-13 |
20110250302 | Composition for Preventing Hair Loss and Promoting Hair Regrowth - Disclosed is a composition for preventing hair loss and promoting hair regrowth. It acts to inhibit the activity of 5α-reductase and is useful as a hair regrowth agent as assayed in animal and clinical trials. | 2011-10-13 |
20110250303 | FEED FOR PREVENTING AND/OR TREATING DISEASES CAUSED BY CLOSTRIDIUM BACTERIUM IN LIVESTOCK, AND AGENT AGAINST CLOSTRIDIUM - The present invention provides a controlling agent for a disease caused by a | 2011-10-13 |
20110250304 | COSMETIC COMPOSITION WITH ANTI-FREE RADICAL ACTIVITY - Cosmetic compositions with anti-free radical activity have been developed. Such compositions preferably contain an association of at least the following three substances with anti-free radical activity: an extract of emblica, idebenone and N-acetylcysteine. | 2011-10-13 |
20110250305 | MOLD DEVICE - Disclosed herein is a mold device. The mold device includes: an injection molding core; an ejector pin disposed under the core to pull the core in injection; a first magnet disposed at the lower end of the core; and a second magnet disposed at the upper end of the ejector pin to attract the first magnet and prevent the core from being biased. | 2011-10-13 |
20110250306 | APPARATUS FOR FORMING A PIPE FITTING - A pipe fitting includes a polymeric body molded into and fixedly connected to a metallic body, so that the metallic body extends around the polymeric body. The polymeric body extends around and is contiguous with a passageway of the pipe fitting, and at least partially defines a first opening of the passageway that is for being mated to a polymeric pipe. The metallic body extends around and is contiguous with the passageway, and at least partially defines a second opening of the passageway that is for being mated to a metallic pipe. | 2011-10-13 |
20110250307 | INSTALLATION FOR THE PRODUCTION OF CONTAINERS, COMPRISING A RETRACTABLE TRANSFER WHEEL - An installation ( | 2011-10-13 |
20110250308 | ELECTROSPINNING APPARATUS, METHODS OF USE, AND UNCOMPRESSED FIBROUS MESH - Embodiments of the present disclosure provide electrospinning devices, methods of use, uncompressed fibrous mesh, and the like, are disclosed. | 2011-10-13 |
20110250309 | STAMPER INCLUDING A MICRO PATTERN - The present invention relates to stampers having micro patterns, and more specifically, the present invention relates to a stamper which enables to emit a color or form a character or a predetermined shape on a surface of an injection molded product owing to a pattern in a case the pattern is formed on the injection molded product by the stamper. | 2011-10-13 |
20110250310 | WHEY PROTEIN COMPOSITIONS, METHODS AND USES - The present invention provides various whey protein compositions as nutritional formulations suitable for use as ready-to-use liquid compositions that are shelf-stable and contains high level of intact whey protein content. The present invention further provides the methods of making such compositions. | 2011-10-13 |
20110250311 | FORMULATIONS AND METHODS FOR MAINTAINING NORMAL HORMONE LEVELS - The invention provides methods for maintaining normal levels of catecholamines, glucocorticoids, adrenal steroids, and their related hormones in a human subject by administering | 2011-10-13 |
20110250312 | METHODS AND SYSTEMS FOR PRODUCING ETHANOL USING RAW STARCH AND SELECTING PLANT MATERIAL - The present invention relates to methods for producing high levels of alcohol during fermentation of plant material, and to the high alcohol beer produced. The method can include selecting plant material. Selecting can include excluding plant material that has been exposed to high temperatures or that has had high moisture content. | 2011-10-13 |
20110250313 | Protein Hydrolysate Compositions - The present invention provides protein hydrolysate compositions, processes for making protein hydrolysate compositions, and food products comprising protein hydrolysate compositions. The protein hydrolysate compositions generally comprise a mixture of polypeptides enriched in a 47 kDa fragment, wherein between about 10% and about 66% of the polypeptides are the 47 kDa fragment. | 2011-10-13 |
20110250314 | Activated Cranberry Powder - An active fruit powder is produced from fruits which include components resistant to digestion. The process includes macerating the fruit to yield a pomace slurry adding water to the process if necessary and adding enzymes to the slurry in an amount sufficient to provide the molecular breakdown of the cranberry. Examples of suitable enzymes include pectin esterase (pectinase), depolymerase, cellulase, hemicellulase, manannase, galactosidase, xylanase and glucanase. The slurry is preferably heated and agitated. | 2011-10-13 |
20110250315 | METHOD FOR PREPARING FERMENTED TEA USING BACILLUS SP. STRAINS (As Amended) - Disclosed is a method for manufacturing fermented tea having superior flavor using | 2011-10-13 |
20110250316 | Method of manufacturing meat extract, and meat extract - Meat extract (warm and/or cold blooded animal) having a protein content of at least about 50% or greater and is substantially fluid or pourable at ambient temperature of about 15-25 degrees C. or more. The meat extract may have a viscosity ranging between about 1000 cP to no more than about 40000 cP for temperatures of about 20-80 degrees C. The meat extract may have a protein content of at least about 50%-about 70% with an extract moisture content of about 25%-40%, and a salt content of less than about 5%, e.g., less than 1%. The protein may have a minimum of about 22% of total essential amino acids, e.g., about 3.0% of L-Leucine and/or about 0.2% of L-Tryptophan. Also disclosed is a process of manufacturing a meat extract by extracting meat with water and at least one enzyme, e.g., a proteolytic enzyme, e.g., at least one endopeptidase (amino-endopeptidase and/or at least one carboxy-endopeptidase) and/or at least one exopeptidase, e.g., at least one amino-exopeptidase and/or at least one carboxy-exopeptidase. The extracting may takes place at an extraction temperature of between about 45° C. and about 80° C., e.g., for a period of between about 30 minutes and about 5 hours, and may be followed by subsequent heating to a temperature of between about 90° C. and about 120° C., e.g., between about 15 minutes and about 1 hour. | 2011-10-13 |
20110250317 | INFANT OR FOLLOW-ON FORMULA - The formula of the invention, intended both for infants and young children, comprises at least one LC-PUFA and at least one probiotic. The invention also pertains to methods of strengthening natural immune defences and promoting a healthy mental development in infants or young children by fully or partly feeding them with the said formula. | 2011-10-13 |
20110250318 | COMPOSITIONS AND METHODS FOR FORTIFYING A BASE FOOD TO CONTAIN THE COMPLETE NUTRITIONAL VALUE OF ONE SERVING OF FRUITS AND VEGTABLES ("SFV") FOR HUMAN CONSUMPTION - The described invention provides a method to determine a standard equivalent unit of nutrition in one serving of a weighted composition comprising a basket of fruits and vegetables representing at least 85% of all fruits and vegetables consumed in a defined geographical area; a method to fortify a base food so that the base food contains a standard equivalent unit of nutrition present in at least one serving comprising (i) at least one fruit; (ii) at least one vegetable, or (iii) at least one fruit and at least one vegetable; and a nutritional supplement or food additive comprising a set of nutritive components wherein the set of nutritive components provides at least one standard equivalent unit of nutrition present in one serving of a composition comprising at least one fruit and at least one vegetable. | 2011-10-13 |
20110250319 | DISPOSABLE CAPSULE FOR THE PRODUCTION OF AN AROMATIC BEVERAGE, METHOD AND PROCESS MACHINE FOR MAKING IT - The disposable capsule for the production of an aromatic beverage comprises a container having a closed base which can be perforated for the inlet of water, and an open base closed by at least a filter through which the beverage can exit, said filter having a peripheral edge applied to a peripheral profile of said open base of the container, the peripheral profile of the open base to which the peripheral edge of said filter conforms having a peripheral development at a variable height with respect to the axis of the container. | 2011-10-13 |
20110250320 | Package with Indicia for Consumer Recall and Excitement - A package comprising a graphic representation of a face construct. The face construct can comprise a background forming a facial region, a first eye and a second eye, and text in the form of a plurality of letters that form a concave contour. A package for holding a food product having a nutrition fact statement printed thereon. The package further comprises a first notation positioned to identify at least one of the nutritional parameters and/or one of the ingredients of the nutrition fact statement, wherein the first notation comprises a symbol, logo, image, or text linking the nutritional parameter or the ingredient to a statement about the food product. Methods of increasing consumer recall, increasing consumer excitement, and educating consumers using packaging with a graphic representation of a face construct. | 2011-10-13 |
20110250321 | OVEN BAKED POCKET CHEESE - The present invention is directed to a baked cheese product having two opposing pieces of exterior cheese having outer edges. An interior food product of a different type of cheese or a non-cheese product has dimensions less than the dimensions of the exterior cheese. The interior food product is positioned between the opposing slices of the exterior cheese such that outer edges of the opposing slices of the exterior cheese are placed together. The outer edges are bonded by heat to create a bond sufficient to prevent leakage of the interior food product. | 2011-10-13 |
20110250322 | Plastic Packaged Nutritional Liquids Comprising HMB - Disclosed are nutritional compositions comprising a plastic package and a nutritional liquid contained therein, wherein the nutritional liquid comprises beta-hydroxy-beta-methylbutyrate (HMB) and at least one of fat, protein, and carbohydrate. It has been found that HMB provides a buffering effect in the nutritional liquid to thus minimize an acidic pH shift that is more prevalent in plastic packages, and thus help maintain product stability over time. | 2011-10-13 |
20110250323 | MICROWAVABLE REFRIGERATED SCRAMBLED EGGS AND PROCESS - A microwavable, refrigerated scrambled egg composition. The composition comprises a first component that is frozen precooked egg portions. At least about 50% by weight of the frozen egg portions are pieces that are at least about ½ inch in one dimension. The second component is a slurry comprising pasteurized liquid egg and pregelatinized modified food starch. The precooked egg portions are from about 50% to about 85% by weight of the total scrambled egg composition and the slurry is from about 15% to about 50% by weight of the total scrambled egg composition. Processes for making and methods of using the microwavable, refrigerated scrambled egg composition are also provided. | 2011-10-13 |